A XM não fornece serviços a residentes nos Estados Unidos da América.

A XM não fornece serviços a residentes nos Estados Unidos da América.
T
T

ThermoFisher

Notícias

Reuters - Há 22 horas

U.S. STOCKS Avery Dennison, Snap-On, Avadel Pharma

BUZZ-U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street gained on Thursday, with the S&P 500 and the Dow touching intraday record highs, driven by TSMC's upbeat forecast and a bigger-than-expected rise in monthly retail sales indicating a strong U.S.
A
B
C
E
I
N
N
R
S
S
S
U
U
U
U
T
U
W
W
A
E
M
S
Reuters - Há 1 dia

U.S. STOCKS PPG Industries, Travelers, ShiftPixy

BUZZ-U.S. STOCKS ON THE MOVE-PPG Industries, Travelers, ShiftPixy Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes were set to rise on Thursday, with an upbeat forecast from TSMC boosting semiconductor stocks, while a bigger-than-expected rise in September retail sales pointed to a strong U.S.
A
A
B
C
C
E
I
N
R
S
U
U
S
T
U
W
W
P
R
Reuters - Há 1 dia

US life sciences firms get lift from Sartorius' results

BUZZ-US life sciences firms get lift from Sartorius' results ** Shares of US life sciences firms rise after German peer Sartorius's SATG.DE better-than-expected bioprocessing order intake in its nine-month results ** Premarket, Danaher DHR.N up 3.4%, Thermo Fisher Scientific TMO.N up 2.1% and Waters WAT.N up 1.7% ** Sartorius' order intake rose 6.6
T
W
Reuters - Há 2 dias

U.S. STOCKS Wave Life Sciences, Dominion Energy, Voyager Therapeutics

BUZZ-U.S. STOCKS ON THE MOVE-Wave Life Sciences, Dominion Energy, Voyager Therapeutics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq were little changed on Wednesday, with declines in heavily weighted technology megacaps limiting gains as investors turned to small-cap and financial stocks after a slew of upbeat bank earnings.
A
A
I
J
S
U
U
G
T
W
A
Reuters - Há 2 dias

U.S. STOCKS Wave Life Sciences, Dominion Energy, Voyager Therapeutics

BUZZ-U.S. STOCKS ON THE MOVE-Wave Life Sciences, Dominion Energy, Voyager Therapeutics The Dow regained some lost ground on Wednesday although the S&P 500 and the Nasdaq stumbled, dragged lower by declines in megacap technology stocks, while the broader market gained from upbeat quarterly earnings from banks, notably Morgan Stanley. .N At 11:32 ET, the Dow Jones Industrial Average .DJI was up 0.4% to 42,924.64 at 11:34, pares gain.
A
A
C
D
I
S
J
U
U
U
G
T
W
A
Reuters - Há 2 dias

Bernstein expects a 'not so scary' Q3 for US life sciences firms

BUZZ-Bernstein expects a 'not so scary' Q3 for US life sciences firms ** Brokerage Bernstein expects a "not so scary" Q3 earnings season for U.S. life sciences and tools firms, which "would be a real treat" for investors ** "With the recovery timeline for life science tools continuing to push out (further), some investors feel like they have been t
A
I
T
W
Reuters - Há 2 semanas

Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show

EXCLUSIVE-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show Thermo Fisher's Greenville, N.C. plant has been found in breach of US FDA regulations, including twice this year FDA's most recent inspection of Thermo Fisher plant found shortfalls in manufacturing of Sanofi's and AstraZeneca's Beyfortus RSV treatment Sanofi says the FDA findings were addressed and all Beyfortus doses were approved by FDA before they were shipped Adds graphic By Patrick Wingrove Oct 4 (Reu
A
S
T
Reuters - Há 2 semanas

Thermo Fisher falls after Reuters report on breaches at North Carolina plant

BUZZ-Thermo Fisher falls after Reuters report on breaches at North Carolina plant ** Shares of contract drug manufacturer Thermo Fisher TMO.N down 1.6% at $591.31 premarket ** One of TMO's manufacturing plants has repeatedly breached rules meant to ensure drugs are free of contamination in the last decade, Reuters repored , citing FDA documents ** The plant, located in Greenville, North Carolina is among the largest contract drug manufacturing plants in the U.S.
U
T
Reuters - Há 2 semanas

Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show

CORRECTED-EXCLUSIVE-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show Corrects paragraph 26 to Novo Holdings from Novo Nordisk Thermo Fisher's Greenville, N.C. plant has been found in breach of US FDA regulations, including twice this year FDA's most recent inspection of Thermo Fisher plant found shortfalls in manufacturing of Sanofi's and AstraZeneca's Beyfortus RSV treatment Sanofi says the FDA findings were addressed and all Beyfortus doses were approved by FDA b
A
S
T
Reuters - Há 3 semanas

Thermo Fisher Scientific Expands Oral Solid Dose Development And Manufacturing Capabilities Across North America

BRIEF-Thermo Fisher Scientific Expands Oral Solid Dose Development And Manufacturing Capabilities Across North America Sept 26 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC EXPANDS ORAL SOLID DOSE DEVELOPMENT AND MANUFACTURING CAPABILITIES ACROSS NORTH AMERICA Source text for Eikon: ID:nBwc3wlpHa Further company coverage
T
Reuters - Há 4 semanas

ASML supplier NTS Group opens Singapore plant

ASML supplier NTS Group opens Singapore plant AMSTERDAM, Sept 20 (Reuters) - NTS Group, a Dutch-based maker of "mechatronic" equipment used by semiconductor firms including neighbouring giant ASML ASML.AS , on Friday opened a major new assembly and manufacturing plant in Singapore. Mechatronics integrate mechanical, electronics and software systems. NTS is known as a supplier of highly complex systems used in metrology, where top names include Lam Research, Applied Materials AMAT.O , Thermo Fish
A
L
T
Reuters - Há 4 semanas

U.S. Factset, FedEx, Thermo Fisher Scientific

U.S. RESEARCH ROUNDUP-Factset, FedEx, Thermo Fisher Scientific Sept 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Factset, FedEx and Thermo Fisher Scientific on Friday. HIGHLIGHTS * Arthur J. Gallagher & Co. AJG.N : RBC raises target price to $320 from $310 * Factset FDS.N : RBC raises target price to $503 from $464 * FedEx Corp FDX.N : Baird cuts target price to $320 from $340 * IQVIA Holdings Inc IQV.N : Baird
A
A
A
B
D
E
N
X
T
A
D
I
L
P
Reuters - Há 1 mês

U.S. Constellation Energy, Eli Lilly, Talen Energy

U.S. RESEARCH ROUNDUP-Constellation Energy, Eli Lilly, Talen Energy Sept 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Eli Lilly and Talen Energy, on Friday. HIGHLIGHTS * Constellation Energy Corp CEG.O : Jefferies initiates with hold rating; target $183 * Eli Lilly LLY.N : JP Morgan raises target price to $1,100 from $1,050 * Moderna MRNA.O : JP Morgan cuts to underweight from neutral * Vo
A
C
C
F
F
H
H
H
I
K
W
F
D
T
Z
A
A
D
E
H
L
Reuters - Há 1 mês

Buyout barons’ dirty secret shows hard times ahead

BREAKINGVIEWS-Buyout barons’ dirty secret shows hard times ahead The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Liam Proud LONDON, Sept 12 (Reuters Breakingviews) - Private-equity dealmakers like to boast about the ways they improve companies, like supercharging growth or trimming costs. The evidence, however, suggests that buyout barons owe a large chunk of their success to rising valuation multiples instead.
U
T
Reuters - Há 2 meses

Agilent beats quarterly results on strong demand from biotech clients

Agilent beats quarterly results on strong demand from biotech clients Aug 21 (Reuters) - Agilent Technologies A.N on Wednesday beat Wall Street estimates for third-quarter profit and revenue, banking on strong demand for its medical tools and equipment used in clinical studies. "While market conditions continued to be challenged during the quarter, we saw steady signs of improvement as anticipated", said CEO Padraig McDonnell.
A
T
Reuters - Há 2 meses

Bio-Techne meets Q4 profit estimates on demand for its diagnostics products

Bio-Techne meets Q4 profit estimates on demand for its diagnostics products Aug 7 (Reuters) - Bio-Techne TECH.O reported fourth-quarter profit in line with estimates on Wednesday as growth in the diagnostics and genomics unit offset weakness in its protein sciences unit. The Minnesota-based company posted an adjusted profit of 49 cents per share, meeting analysts' expectations according to LSEG data.
T
Reuters - Há 2 meses

Leerink views Lilly and Sarepta as defensive stocks in turbulent market

BUZZ-Leerink views Lilly and Sarepta as defensive stocks in turbulent market ** Brokerages Leerink Partners says Eli Lilly LLY.N and Sarepta Therapeutics SRPT.O are among stocks it expects to outperform the broader market in "this turbulent period" of recession concerns ** Brokerage expects strong performance from the weight-loss and diabetes drug maker LLY on Wed, when it reports its earnings ** SRPT is a "a potential haven for investors seeking downside protection in a choppy market" due to po
A
B
M
T
Reuters - Há 2 meses

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

UPDATE 1-Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims Adds response from Novartis in paragraph 3 By Blake Brittain Aug 5 (Reuters) - Novartis NOVN.S and Viatris VTRS.O were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
N
T
Reuters - Há 2 meses

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims By Blake Brittain Aug 5 (Reuters) - Novartis NOVN.S and Viatris VTRS.O were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development. The estate of Henrietta Lacks accused Novartis and Viatris of unlawfully profiting from the use of the "HeLa" cells to create drugs that have been "integral to their market pre
N
T
Reuters - Há 3 meses

China's stuttering recovery darkens global corporate growth outlook

ANALYSIS-China's stuttering recovery darkens global corporate growth outlook By Medha Singh Aug 2 (Reuters) - Global burger chains to car manufacturers are increasingly feeling the pinch from a faltering recovery in the world's No. 2 economy , China, and are strapping in for a bumpy ride ahead. A protracted downturn in the property market and high levels of job insecurity have knocked the wind out of a fragile recovery in China, a global trading powerhouse, and the effects of its slowdown can be
A
B
B
B
H
K
L
L
M
P
Q
S
T
T

Condições

Ativos populares

Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.

Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.

Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.

Aviso de risco: O seu capital está em risco. Os produtos alavancados podem não ser adequados para todos. Recomendamos que consulte a nossa Divulgação de Riscos.